BREYANZI (lisocabtagene maraleucel)
STN# BLA 125714
Proper Name: lisocabtagene maraleucel
Tradename: BREYANZI
Manufacturer: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Indication:
- For the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (including DLBCL arising from indolent lymphoma), high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B.
Product Information
- Package Insert - BREYANZI
- Demographic Subgroup Information – lisocabtagene maraleucel [BREYANZI]
Refer to Section 1.1 of the Clinical Review Memo for information about participation in the clinical trials and any analysis of demographic subgroup outcomes that is notable.